Aiming at "gradual freezing"!

Article source: Pharmaceutical Guanlan

Recently, Magpie Medicine's Class 1 new drug nitroxazine for the treatment of amyotrophic lateral sclerosis (ALS) has obtained the implied approval of the US FDA clinical trial, and a phase 1 clinical bridging trial will be launched in the United States

Founded in 2011, Magpie Medicine is a clinical-stage company focusing on the research and development of innovative treatments for cardiovascular and mitochondrial diseases

Nitrazine is a class 1 chemical innovation drug exclusively transferred from Jinan University by Magpie Medicine, and it has a unique mechanism of action

In China, nitroxazine tablets are currently undergoing a phase 2 clinical study for the treatment of ALS, aiming to evaluate the efficacy, safety and PK characteristics of nitroxazine tablets in ALS patients

Amyotrophic lateral sclerosis, commonly known as "gradual freezing syndrome", is a fatal neurodegenerative disease characterized by the progressive degeneration of brain and spinal cord motor neurons

Note: The original text has been deleted

Reference materials:

[1] Magpie Medicine's class 1 chemical innovative drug for treatment of amyotrophic lateral sclerosis, nitroxazine tablets, was approved by the US FDA for clinical trials.